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ABSTRACT
Clinical inertia is defined as the failure to
establish appropriate targets and escalate
treatment to achieve treatment goals. It
accounts for a significant proportion of failure
to achieve targets in the management of
diabetes and contributes to up to 200,000
adverse diabetes- related outcomes per year.
Despite a growing awareness of the
phenomenon, and newer, better-tolerated
agents for the control of diabetes, there has
been little improvement over the last decade in
the prevalence of clinical inertia. Although
common-place in clinical practice, clinical
inertia does not appear to affect clinical trials.
There are lessons that may be translated from
these randomised controlled trials to clinical
practice, which that may improve the care for
those with diabetes. Key amongst these
interventions are good education, clear
treatment strategy and more time for
interaction between physician and patients, all
of which appears to reduce clinical inertia as
evidenced by the ‘‘placebo effect’’ of clinical
trials. We plan to review here, the lessons that
can be learnt from clinical trials and how these
may translate to better care for people with
diabetes.
INTRODUCTION
Clinical inertia, the failure to establish
appropriate targets and escalate treatment to
achieve treatment goals, is responsible for
substantial preventable complications of
diabetes with the associated excess in direct
and indirect health care costs. If ‘‘clinical
inertia’’ was an intervention associated with
this increased risk of complications, it would
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rapidly be withdrawn pending safety analyses.
However, the lack of appropriate escalation of
treatment is accepted in every day practice. The
concept of clinical inertia is not new. Despite
the availability of effective glucose-lowering
therapies with low risk of hypoglycaemia and
weight gain, there is a persistent failure to
achieve the established targets in almost half
of people with diabetes.
PREVALENCE OF CLINICAL INERTIA
Clinical inertia is a worldwide phenomenon,
particularly when considering initiation of
insulin in persons with type 2 diabetes. In the
United States, for example, an observational
study in 3,891 persons with diabetes registered
with a health maintenance organisation
reported a delay of almost 3 years in patients
with consistently elevated glycosylated
haemoglobin (HbA1c) levels despite dual once
a day (OAD) therapy (metformin and
sulfonylurea) [1, 2]. Further, a multinational,
26-week observational study reported an HbA1c
level of 8.9% (74 mmol/mol) at insulin
initiation [3]. A Canadian study in adults with
diabetes aged C65 years (n = 2,502) found that,
although diabetologists are more likely to
initiate insulin based on poor glycaemic
control (HbA1c [8%), only 45% intensified
treatment overall compared with 37% of
primary care physicians [1]. Unfortunately,
this reluctance influences the patient
perceptions of diabetes therapies and may
deter them from accepting insulin therapy [1,
4, 5]. The fear of side effects can cause hesitancy
to comply with insulin therapy [6].
Paradoxically, the dialogue prior to insulin
initiation often vilifies the therapy itself.
Insulin may also be perceived as a punishment
rather than a necessary part of the management
of this progressive condition. In doing so,
physicians can be the root cause of non-
adherence to their own prescriptions [7].
There is also reluctance to initiate
combination therapies in early-stage disease;
movement beyond monotherapy in patients
who are asymptomatic is often slow,
particularly when faced with a lack of
confidence or experience with newer therapies.
Once therapy is initiated, there is also a lack of
organisational mechanisms to help physicians
monitor response to therapy. Guidelines
indicate that the benefits, or otherwise, of
therapy should be monitored and if target is
not achieved, therapy adjusted. This, however,
very rarely takes place, particularly with the
generic familiar treatments, such as
sulphonylureas. In the absence of good
mechanisms to monitor response to therapy
prior to review, further unnecessary delays often
occur prior to any changes in therapy. In these
settings, a ‘wait until next visit’ approach is
often adopted, particularly when faced with soft
rationalisations by patients to avoid treatment
intensification [7]. Yet, the increased awareness
and methods of quantification have done little
to improve outcomes. Time to intensification of
treatment has not significantly improved since
1990s to date [2].
THE COST OF CLINICAL INERTIA
Part of the rationalisation of clinical inertia is
embedded in the ‘‘first do no harm’’ principle.
This results in the perception that non-
intervention is better than risking the side
effects of treatment. Herein lies one of the
major difficulties in preventative medicine; for
the event, such as the stroke, deterioration in
vision or foot ulcer that has been prevented is
never visible, whereas the complications of
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treatment, such as hypoglycaemia or weight
gain, are all too apparent. Epidemiological data,
however, suggest that for every 20 people with
type 2 diabetes with an HbA1c value 1% above
the 7% target, one will suffer a microvascular
complication within 5 years. A low-density
lipoprotein (LDL) cholesterol level 30 mg/dl
above goal will result in a myocardial
infarction or stroke, and for every 20 patients
with a blood pressure 10 mmHg above target,
one will suffer a myocardial infarction or stroke
and one will progress their microvascular
disease within the same 5-year period. Analysis
of National Health and Nutrition Examination
Survey (NHANES) data suggests that only
approximately 20% of people with diabetes are
achieving all of these targets [8]. Therefore, in
North America alone, where there are
approximately 36.7 million people with
diabetes, this equates to nearly 30 million
people who are inadequately controlled. This
is responsible for an excess of at least 200,000
avoidable diabetes-related complications per
year, which in turn is responsible for billions
of dollars in excess health care charges and tens
of thousands of premature deaths. If these
events were occurring as a result of inaccurate
or inappropriate prescriptions it would be
regarded as an unacceptable prescribing error,
likely to engender public outrage. Paradoxically,
there is an acceptance of this inertia where the
problem is a lack of appropriate prescription
rather than administering inappropriate
medication.
CAUSES OF CLINICAL INERTIA
Part of the acceptance of clinical inertia is
because there is no single identifiable fault.
Rather, it is a multifactorial condition, with
contributory factors from the people with
diabetes, the physicians and the system in
which they operate.
Physician Factors
Whereas physicians are able to accurately
identify clinical inertia in their peers, they
consistently overrate the quality of the care
they provide. Additionally, they substantially
underestimate the number of their own patients
that are not at targets. Physicians are also more
prone to making ‘‘soft excuses’’ to avoid
intensification; a lack of time to adequately
discuss the new strategy, blaming the patient
for non-compliance or adopting a paternalistic
approach. Finally, many physicians may lack
the appropriate support, knowledge or training
to manage multiple chronic diseases. This is
particularly true in the management of type 2
diabetes, where therapeutic options have
expanded considerably in a relatively short
time frame mirrored by substantial changes in
guidelines. These guidelines further complicate
the management strategy of diabetes, as
physicians are increasingly recommended to
individualise treatment goals. There are,
however, no clear recommendations as to how
to establish these goals. Paradoxically,
therefore, the drive to individualise care
actually encourages clinical inertia through
lack of clarity.
There are three potential points on the
pathway to good control where these can
fail—setting the appropriate target, initiating
appropriate treatment and modifying the
treatment in response to outcomes.
Establishing Goals
Physicians tend to set targets based on
treatment strategies with which they are most
familiar, appropriate for the individual or not.
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To date there is only one study which has
evaluated the feasibility of individualising
treatment targets [9]. Despite being provided
clear guidance on how to personalise targets,
conventional targets of around 7% were still set,
demonstrating inertia of a different sort—the
reluctance to move away from conventional
targets and therefore potentially overtreat
certain individuals.
Individualising treatment targets often
provides an opportunity for ‘‘false reporting’’
of success, allowing the goal to retrospectively
move to meet achieved value. Often this may be
appropriate and indeed these goals should be in
a permanent state of flux reflecting the complex
progressive nature of diabetes. However, in such
time-varying processes, goals should reflect the
anticipated changes. Such forward planning
facilitates realistic target setting with
appropriate thresholds for action. Clear
documentation and review on a regular basis
allows coordination whilst demonstrating the
reality of individualising care.
Systemic Contributors to Clinical Inertia
Older guidelines that promoted universal
algorithmic pathways triggered a different type
of clinical inertia. When faced with such goals
and protocols to achieve them, physicians often
feel a sense of futility. Furthermore, this focus
on goal-setting pathology management
overshadows the need for appropriate action
and grossly under-recognises the importance of
basic communication between patient,
physician and within the multidisciplinary
team. This is particularly true in the primary
care setting where physicians tend to operate in
isolation. The resultant reactive, rather than
proactive, approach to management leads to
intensification of diabetes treatment, and
specialist support is only requested once the
glycaemic control has been lost and, in effect,
waiting until complications have arisen before
appropriate preventative strategies are engaged.
Time constraints further contribute to the
delays in appropriate intensification of therapy
[10]. Clinical trials offer extended, frequent
visits demonstrating a significant ‘‘placebo-
effect’’. Unlike quality of life measures,
glycaemic control is unlikely to be directly
affected by the level of patient/physician
contact time. However, increased frequency of
visits and engagement may offer other
mechanisms for reduction of clinical inertia.
Regular scheduled visits encourage shorter-term
goal setting with established timelines and
planned interventions if these are not met.
Clinical trials have additional transferable
features that may further reduce clinical inertia;
trial protocols provide decision support that
leaves little ambiguity about required
interventions. The final, potentially
transferable, lesson from clinical trials is the
degree of accountability at each visit and
introducing clear clinical record forms to
facilitate adherence to protocols, requiring a
systematic record of results, actions
implemented and justifications of any
deviations from the protocols.
Patient Factors Contributing to Clinical
Inertia
The causes of clinical inertia do not solely lie
with physicians. Non-adherence to lifestyle
modifications and prescribed drug treatments
is estimated to count up to nearly 100% [11].
The underlying reasons for this are unclear.
Interestingly, social and environmental
pressure may be the strongest modulators for
‘‘required’’ lifestyle changes. The importance of
socio-economic factors for diabetes outcomes
has recently been demonstrated by a population
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wide analysis of the consequences of weight loss
and regain driven by an economic crisis in Cuba
[12]. In this survey, an average population wide
*5.5 kg weight loss was associated with rapid
significant declines in diabetes and heart disease
prevalence, whereas a weight rebound led to a
diabetes prevalence that even exceeded pre-
crisis levels [12].
Patient understanding of, and engagement
with, their treatment can be a crucial
determinant of adherence [13] as it may be
adversely influenced by attitudes, negative
media publicity and resultant misperception
[14, 15]. Although no research has
demonstrated the role of positive media
publicity, a logical extrapolation of this is that
positive publicity may encourage a willingness
to intensify treatment on behalf of the patient.
This approach has been effective in conditions
such as erectile dysfunction and stress
incontinence and would be expected to reduce
clinical inertia, particularly if the positive
message is focused on diabetes rather than
specific pharmaceutical agents.
TACKLING CLINICAL INERTIA
Identifying the causes of clinical inertia is only a
small step in reducing the excess burden of
undertreated diabetes. There have been several
studies attempting to address the issue with
limited success. One of the limiting factors of
these studies is that they have each attempted
single interventions to challenge a
multifactorial condition. When considering
each of the factors to be discussed, we ask the
reader to remember how these can only work as
part of a combination strategy. Still, prior to
developing strategies, a clear definition of
clinical inertia is required. Older ‘‘one size fits
all’’ protocols are no longer applicable; the lack
of an individualised target is the evidence of
clinical inertia itself.
The therapeutic goal may be fluid. The
reality of patient factors such as forgetfulness
and real-world impediments may make
previously set targets unachievable despite all
good intentions and every effort. In such
circumstances, targets should be amended to
concede that previous targets are unachievable
or inappropriate with available tools. This must
be distinguished from retrospective amendment
of targets to excuse clinical inertia.
Accountability Through Incentivisation
Accountability between patient and physician is
difficult, particularly as ‘‘soft reasoning’’
resulting in fewer tablets and less
intensification is perceived as a positive
outcome by the patient. However, considering
the implications of chronic, inadequate
metabolic control, personal and economic
direct and indirect costs, several providers
have elected to provide financial incentives for
good metabolic control. In 2003, the UK
National Health Service (NHS) renegotiated
the primary care general practitioners’ contract
to include a ‘‘pay-per-performance’’ scheme.
This quality and outcomes framework (QOF)
linked 129 indicators covering different areas
including diabetes, and provided a pecuniary
reward for achieving targets. Among these, 16
points, each worth £124.60, were awarded for
achieving an HbA1c of at\7.5% in at least 50%
of people with diabetes. This financial
incentivisation of better metabolic control was
associated with an increase from 39.7% in 2006
to 52.1% in 2008 of people with diabetes
achieving an HbA1c of \7.5% in the UK.
Additionally, the number of patients with
poor control (i.e. [10%) reduced from 11.8%
to 10.1%, suggesting the intervention had also
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improved the general approach to diabetes, not
just chasing the 50% target to receive the
reward. It must be acknowledged that this
time period also saw the introduction of the
dipeptidyl peptidase-4 (DPP-4) inhibitors,
enabling targets to be achieved with less
hypoglycaemia and weight gain, thereby
making realising targets more acceptable to
the people with diabetes. The process of
incentivised management, however, did not
necessarily provide additional doctor–patient
contact time with the population as a whole.
Therefore, to achieve these targets, increased
time intervening in people with diabetes, may
come at a cost of less time available to people
with other non-incentivised long-term
conditions, potentially to their long-term
detriment.
Increased Direct Patient Contact Time
Clinical trials usually commence with high-
frequency screening visits, followed by a series
of more frequent visits to initiate and intensify
care, before a stabilised visit regimen
approximately 3–4 months apart. These trials
usually report good early glycaemic control that
is sustained for the duration of the study. There
are many reasons why this increased frequency
of visits may improve control, beyond the
increased opportunity to intensify care and
better monitoring of response to therapy. The
increased frequency, particularly at the outset of
the disease, reinforces the severity of the disease
to the persons with diabetes, thereby reducing
resistance to escalate intervention. It offers the
opportunity for regular educational input, in
digestible packages, and allows development of
a good rapport. Finally, the patient learns by
experience that frequent review and adjustment
of therapy is a part of good diabetes care rather
than a sign of treatment failure. There are, of
course, cost implications of increased frequency
of visits, extra investigations and the increased
prescribing, however, it would be anticipated
that this would be ameliorated in the long-term
by the reduced complications.
IN SUMMARY
The causes of clinical inertia are multifactorial,
with contributory elements from people with
diabetes, physicians and the system within
which they work. One of the key elements
appears to be a lack of open communication in
both directions allowing the person with
diabetes to understand the gravity of their
diagnosis and engage them in treatment
choices, whilst the patient equally may not
express their willingness, nor comply with
attempts to escalate therapies to improve their
health.
Clinical trials are not affected by clinical
inertia, however, these protocols are expensive
to run and cannot be generalised into general
practice. Yet, there are valuable lessons to be
learnt from these trials that may be transferable
to daily practice. Further work is required to
assess the comparative costs and effectiveness of
each individual element of the clinical trial
strategies either alone or in combination to
reduce the burden of clinical inertia.
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